消化器疾患治療薬の世界市場 2023-2027

消化器疾患治療薬市場は2022-2027年に170億7,434万米ドル、予測期間中のCAGRは6.67％で成長すると予測されています。

当レポートでは、消化器疾患治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、消化器疾患の罹患率の増加、消化器治療薬の新製品上市、生物学的製剤や標的治療薬に対する需要の増加によって牽引されています。

本調査では、今後数年間の消化器疾患治療薬市場成長を牽引する主要因の1つとして、栄養療法の利用可能性を挙げています。また、微生物ベースの治療法の出現や、在宅療法と相まってセルフメディケーションの増加も、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2022
• 市場の見通し 2022-2027

第4章 市場規模実績

• 消化器疾患治療薬の世界市場 2017-2021
• 薬剤クラス別セグメント分析 2017-2021
• タイプ別セグメント分析 2017-2021
• 地域別セグメント分析 2017-2021
• 国別セグメント分析 2017-2021

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：薬剤クラス別

• 市場セグメント
• 比較：薬剤クラス別
• 抗炎症剤および免疫抑制剤：市場規模と予測 2022-2027
• 酸中和剤：市場規模と予測 2022-2027
• その他：市場規模と予測 2022-2027
• 市場機会：薬剤クラス別

第7章 市場セグメンテーション：タイプ別

• 市場セグメント
• 比較：タイプ別
• ブランド：市場規模と予測 2022-2027
• ジェネリック：市場規模と予測 2022-2027
• 市場機会：タイプ別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2022-2027
• アジア：市場規模と予測 2022-2027
• 欧州：市場規模と予測 2022-2027
• 世界のその他の地域：市場規模と予測 2022-2027
• 米国：市場規模と予測 2022-2027
• 日本：市場規模と予測 2022-2027
• 中国：市場規模と予測 2022-2027
• ドイツ：市場規模と予測 2022-2027
• フランス：市場規模と予測 2022-2027
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Boston Scientific Corp.
• Eisai Co. Ltd.
• GlaxoSmithKline Plc
• Johnson and Johnson
• Merck and Co. Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• UCB SA

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibits6: Executive Summary - Chart on Market Segmentation by Type
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on global gastrointestinal diseases therapeutics market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Drug class Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibits31: Data Table on Drug Class - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Drug Class
• Exhibits33: Data Table on Comparison by Drug Class
• Exhibits34: Chart on Anti-inflammatory and immunosuppressors - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on Anti-inflammatory and immunosuppressors - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on Anti-inflammatory and immunosuppressors - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Anti-inflammatory and immunosuppressors - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Acid neutralizers - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Acid neutralizers - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Acid neutralizers - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Acid neutralizers - Year-over-year growth 2022-2027 (%)
• Exhibits42: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibits44: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibits45: Data Table on Others - Year-over-year growth 2022-2027 (%)
• Exhibits46: Market opportunity by Drug Class ($ million)
• Exhibits47: Data Table on Market opportunity by Drug Class ($ million)
• Exhibits48: Chart on Type - Market share 2022-2027 (%)
• Exhibits49: Data Table on Type - Market share 2022-2027 (%)
• Exhibits50: Chart on Comparison by Type
• Exhibits51: Data Table on Comparison by Type
• Exhibits52: Chart on Branded - Market size and forecast 2022-2027 ($ million)
• Exhibits53: Data Table on Branded - Market size and forecast 2022-2027 ($ million)
• Exhibits54: Chart on Branded - Year-over-year growth 2022-2027 (%)
• Exhibits55: Data Table on Branded - Year-over-year growth 2022-2027 (%)
• Exhibits56: Chart on Generics - Market size and forecast 2022-2027 ($ million)
• Exhibits57: Data Table on Generics - Market size and forecast 2022-2027 ($ million)
• Exhibits58: Chart on Generics - Year-over-year growth 2022-2027 (%)
• Exhibits59: Data Table on Generics - Year-over-year growth 2022-2027 (%)
• Exhibits60: Market opportunity by Type ($ million)
• Exhibits61: Data Table on Market opportunity by Type ($ million)
• Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits63: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits65: Chart on Geographic comparison
• Exhibits66: Data Table on Geographic comparison
• Exhibits67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits73: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits87: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits88: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits89: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits90: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits91: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibits92: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibits93: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibits94: Data Table on China - Year-over-year growth 2022-2027 (%)
• Exhibits95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits97: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits99: Chart on France - Market size and forecast 2022-2027 ($ million)
• Exhibits100: Data Table on France - Market size and forecast 2022-2027 ($ million)
• Exhibits101: Chart on France - Year-over-year growth 2022-2027 (%)
• Exhibits102: Data Table on France - Year-over-year growth 2022-2027 (%)
• Exhibits103: Market opportunity By Geographical Landscape ($ million)
• Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits105: Impact of drivers and challenges in 2022 and 2027
• Exhibits106: Overview on Criticality of inputs and Factors of differentiation
• Exhibits107: Overview on factors of disruption
• Exhibits108: Impact of key risks on business
• Exhibits109: Vendors covered
• Exhibits110: Matrix on vendor position and classification
• Exhibits111: Abbott Laboratories - Overview
• Exhibits112: Abbott Laboratories - Business segments
• Exhibits113: Abbott Laboratories - Key news
• Exhibits114: Abbott Laboratories - Key offerings
• Exhibits115: Abbott Laboratories - Segment focus
• Exhibits116: AbbVie Inc. - Overview
• Exhibits117: AbbVie Inc. - Product / Service
• Exhibits118: AbbVie Inc. - Key news
• Exhibits119: AbbVie Inc. - Key offerings
• Exhibits120: AstraZeneca Plc - Overview
• Exhibits121: AstraZeneca Plc - Product / Service
• Exhibits122: AstraZeneca Plc - Key news
• Exhibits123: AstraZeneca Plc - Key offerings
• Exhibits124: Bausch Health Companies Inc. - Overview
• Exhibits125: Bausch Health Companies Inc. - Business segments
• Exhibits126: Bausch Health Companies Inc. - Key news
• Exhibits127: Bausch Health Companies Inc. - Key offerings
• Exhibits128: Bausch Health Companies Inc. - Segment focus
• Exhibits129: Bayer AG - Overview
• Exhibits130: Bayer AG - Business segments
• Exhibits131: Bayer AG - Key news
• Exhibits132: Bayer AG - Key offerings
• Exhibits133: Bayer AG - Segment focus
• Exhibits134: Biogen Inc. - Overview
• Exhibits135: Biogen Inc. - Product / Service
• Exhibits136: Biogen Inc. - Key offerings
• Exhibits137: Boehringer Ingelheim International GmbH - Overview
• Exhibits138: Boehringer Ingelheim International GmbH - Business segments
• Exhibits139: Boehringer Ingelheim International GmbH - Key news
• Exhibits140: Boehringer Ingelheim International GmbH - Key offerings
• Exhibits141: Boehringer Ingelheim International GmbH - Segment focus
• Exhibits142: Boston Scientific Corp. - Overview
• Exhibits143: Boston Scientific Corp. - Business segments
• Exhibits144: Boston Scientific Corp. - Key news
• Exhibits145: Boston Scientific Corp. - Key offerings
• Exhibits146: Boston Scientific Corp. - Segment focus
• Exhibits147: Eisai Co. Ltd. - Overview
• Exhibits148: Eisai Co. Ltd. - Business segments
• Exhibits149: Eisai Co. Ltd. - Key offerings
• Exhibits150: Eisai Co. Ltd. - Segment focus
• Exhibits151: GlaxoSmithKline Plc - Overview
• Exhibits152: GlaxoSmithKline Plc - Business segments
• Exhibits153: GlaxoSmithKline Plc - Key news
• Exhibits154: GlaxoSmithKline Plc - Key offerings
• Exhibits155: GlaxoSmithKline Plc - Segment focus
• Exhibits156: Johnson and Johnson - Overview
• Exhibits157: Johnson and Johnson - Business segments
• Exhibits158: Johnson and Johnson - Key news
• Exhibits159: Johnson and Johnson - Key offerings
• Exhibits160: Johnson and Johnson - Segment focus
• Exhibits161: Merck and Co. Inc. - Overview
• Exhibits162: Merck and Co. Inc. - Business segments
• Exhibits163: Merck and Co. Inc. - Key news
• Exhibits164: Merck and Co. Inc. - Key offerings
• Exhibits165: Merck and Co. Inc. - Segment focus
• Exhibits166: Pfizer Inc. - Overview
• Exhibits167: Pfizer Inc. - Product / Service
• Exhibits168: Pfizer Inc. - Key news
• Exhibits169: Pfizer Inc. - Key offerings
• Exhibits170: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibits171: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibits172: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibits173: Takeda Pharmaceutical Co. Ltd. - Key offerings
• Exhibits174: UCB SA - Overview
• Exhibits175: UCB SA - Product / Service
• Exhibits176: UCB SA - Key offerings
• Exhibits177: Inclusions checklist
• Exhibits178: Exclusions checklist
• Exhibits179: Currency conversion rates for US$
• Exhibits180: Research methodology
• Exhibits181: Validation techniques employed for market sizing
• Exhibits182: Information sources
• Exhibits183: List of abbreviations

The gastrointestinal diseases therapeutics market is forecasted to grow by USD 17074.34 mn during 2022-2027, accelerating at a CAGR of 6.67% during the forecast period. The report on the gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of gastrointestinal diseases, new gastrointestinal therapeutics product launches, and increasing demand for biologics and targeted therapies.

Technavio's gastrointestinal diseases therapeutics market is segmented as below:

By Drug Class

• Anti-inflammatory and immunosuppressors
• Acid neutralizers
• Others

By Type

• Branded
• Generics

By Geographical Landscape

• North America
• Asia
• Europe
• Rest of World (ROW)

This study identifies the availability of nutritional therapies as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, the emergence of microbiome-based therapies and an increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.

The report on the gastrointestinal diseases therapeutics market covers the following areas:

• Gastrointestinal diseases therapeutics market sizing
• Gastrointestinal diseases therapeutics market forecast
• Gastrointestinal diseases therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global gastrointestinal diseases therapeutics market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on global gastrointestinal diseases therapeutics market 2017 - 2021 ($ million)
• 4.2 Drug class Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Drug class Segment 2017 - 2021 ($ million)
• 4.3 Type Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Drug Class

• 6.1 Market segments
• Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)
• 6.2 Comparison by Drug Class
• Exhibit 32: Chart on Comparison by Drug Class
• Exhibit 33: Data Table on Comparison by Drug Class
• 6.3 Anti-inflammatory and immunosuppressors - Market size and forecast 2022-2027
• Exhibit 34: Chart on Anti-inflammatory and immunosuppressors - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Anti-inflammatory and immunosuppressors - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Anti-inflammatory and immunosuppressors - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Anti-inflammatory and immunosuppressors - Year-over-year growth 2022-2027 (%)
• 6.4 Acid neutralizers - Market size and forecast 2022-2027
• Exhibit 38: Chart on Acid neutralizers - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Acid neutralizers - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Acid neutralizers - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Acid neutralizers - Year-over-year growth 2022-2027 (%)
• 6.5 Others - Market size and forecast 2022-2027
• Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 6.6 Market opportunity by Drug Class
• Exhibit 46: Market opportunity by Drug Class ($ million)
• Exhibit 47: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 48: Chart on Type - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Type - Market share 2022-2027 (%)
• 7.2 Comparison by Type
• Exhibit 50: Chart on Comparison by Type
• Exhibit 51: Data Table on Comparison by Type
• 7.3 Branded - Market size and forecast 2022-2027
• Exhibit 52: Chart on Branded - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Branded - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Branded - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Branded - Year-over-year growth 2022-2027 (%)
• 7.4 Generics - Market size and forecast 2022-2027
• Exhibit 56: Chart on Generics - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Generics - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Generics - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Generics - Year-over-year growth 2022-2027 (%)
• 7.5 Market opportunity by Type
• Exhibit 60: Market opportunity by Type ($ million)
• Exhibit 61: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Asia - Market size and forecast 2022-2027
• Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.5 Europe - Market size and forecast 2022-2027
• Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 Japan - Market size and forecast 2022-2027
• Exhibit 87: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• 9.9 China - Market size and forecast 2022-2027
• Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.10 Germany - Market size and forecast 2022-2027
• Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.11 France - Market size and forecast 2022-2027
• Exhibit 99: Chart on France - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on France - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on France - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on France - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Abbott Laboratories
• Exhibit 111: Abbott Laboratories - Overview
• Exhibit 112: Abbott Laboratories - Business segments
• Exhibit 113: Abbott Laboratories - Key news
• Exhibit 114: Abbott Laboratories - Key offerings
• Exhibit 115: Abbott Laboratories - Segment focus
• 12.4 AbbVie Inc.
• Exhibit 116: AbbVie Inc. - Overview
• Exhibit 117: AbbVie Inc. - Product / Service
• Exhibit 118: AbbVie Inc. - Key news
• Exhibit 119: AbbVie Inc. - Key offerings
• 12.5 AstraZeneca Plc
• Exhibit 120: AstraZeneca Plc - Overview
• Exhibit 121: AstraZeneca Plc - Product / Service
• Exhibit 122: AstraZeneca Plc - Key news
• Exhibit 123: AstraZeneca Plc - Key offerings
• 12.6 Bausch Health Companies Inc.
• Exhibit 124: Bausch Health Companies Inc. - Overview
• Exhibit 125: Bausch Health Companies Inc. - Business segments
• Exhibit 126: Bausch Health Companies Inc. - Key news
• Exhibit 127: Bausch Health Companies Inc. - Key offerings
• Exhibit 128: Bausch Health Companies Inc. - Segment focus
• 12.7 Bayer AG
• Exhibit 129: Bayer AG - Overview
• Exhibit 130: Bayer AG - Business segments
• Exhibit 131: Bayer AG - Key news
• Exhibit 132: Bayer AG - Key offerings
• Exhibit 133: Bayer AG - Segment focus
• 12.8 Biogen Inc.
• Exhibit 134: Biogen Inc. - Overview
• Exhibit 135: Biogen Inc. - Product / Service
• Exhibit 136: Biogen Inc. - Key offerings
• 12.9 Boehringer Ingelheim International GmbH
• Exhibit 137: Boehringer Ingelheim International GmbH - Overview
• Exhibit 138: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 139: Boehringer Ingelheim International GmbH - Key news
• Exhibit 140: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 141: Boehringer Ingelheim International GmbH - Segment focus
• 12.10 Boston Scientific Corp.
• Exhibit 142: Boston Scientific Corp. - Overview
• Exhibit 143: Boston Scientific Corp. - Business segments
• Exhibit 144: Boston Scientific Corp. - Key news
• Exhibit 145: Boston Scientific Corp. - Key offerings
• Exhibit 146: Boston Scientific Corp. - Segment focus
• 12.11 Eisai Co. Ltd.
• Exhibit 147: Eisai Co. Ltd. - Overview
• Exhibit 148: Eisai Co. Ltd. - Business segments
• Exhibit 149: Eisai Co. Ltd. - Key offerings
• Exhibit 150: Eisai Co. Ltd. - Segment focus
• 12.12 GlaxoSmithKline Plc
• Exhibit 151: GlaxoSmithKline Plc - Overview
• Exhibit 152: GlaxoSmithKline Plc - Business segments
• Exhibit 153: GlaxoSmithKline Plc - Key news
• Exhibit 154: GlaxoSmithKline Plc - Key offerings
• Exhibit 155: GlaxoSmithKline Plc - Segment focus
• 12.13 Johnson and Johnson
• Exhibit 156: Johnson and Johnson - Overview
• Exhibit 157: Johnson and Johnson - Business segments
• Exhibit 158: Johnson and Johnson - Key news
• Exhibit 159: Johnson and Johnson - Key offerings
• Exhibit 160: Johnson and Johnson - Segment focus
• 12.14 Merck and Co. Inc.
• Exhibit 161: Merck and Co. Inc. - Overview
• Exhibit 162: Merck and Co. Inc. - Business segments
• Exhibit 163: Merck and Co. Inc. - Key news
• Exhibit 164: Merck and Co. Inc. - Key offerings
• Exhibit 165: Merck and Co. Inc. - Segment focus
• 12.15 Pfizer Inc.
• Exhibit 166: Pfizer Inc. - Overview
• Exhibit 167: Pfizer Inc. - Product / Service
• Exhibit 168: Pfizer Inc. - Key news
• Exhibit 169: Pfizer Inc. - Key offerings
• 12.16 Takeda Pharmaceutical Co. Ltd.
• Exhibit 170: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 171: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Key offerings
• 12.17 UCB SA
• Exhibit 174: UCB SA - Overview
• Exhibit 175: UCB SA - Product / Service
• Exhibit 176: UCB SA - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 177: Inclusions checklist
• Exhibit 178: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 179: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 180: Research methodology
• Exhibit 181: Validation techniques employed for market sizing
• Exhibit 182: Information sources
• 13.5 List of abbreviations
• Exhibit 183: List of abbreviations